ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis

American Journal of Pathology

Volumn 178, Issue 1, 2011, Pages 69-78

  Bepler, Gerold ^a   Olaussen, Ken André ^b   Vataire, Anne Lise ^b   Soria, Jean Charles ^b   Zheng, Zhong ^c   Dunant, Ariane ^b   Pignon, Jean Pierre ^b   Schell, Michael J ^c   Fouret, Pierre ^a   Pirker, Robert ^d   Filipits, Martin ^d   Brambilla, Elisabeth ^e  

^a KARMANOS CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NAVELBINE; REGULATORY SUBUNIT OF RIBONUCLEOTIDE REDUCTASE 1; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY;

EID: 79251503287     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.029     Document Type: Article

References (29)

1. Reed E: ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005, 11:6100-6102
2. Simon GR, Sharma S, Cantor A, Smith P, Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127:978-983
3. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon J-P, Tursz T, Le Chavalier T, Soria J-C: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991
4. Wei Q, Cheng L, Hong WK, Spitz MR: Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996, 56:4103-4107
5. Cheng L, Spitz MR, Hong WK, Wei Q: Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000, 8:1527-1530 (Pubitemid 30601644)
6. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G: RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 2006, 24: 4731-4737
7. Stubbe J: Ribonucleotide reductases in the twenty-first century. Proc Natl Acad Sci U S A 1998, 95:2723-2724
8. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766
9. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325
10. Bergman A, Eijk P, van Haperen V, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters G: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as a major determinant. Cancer Res 2005, 65:9510-9516
11. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825
12. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007, 120: 1355-1363
13. Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC: Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms in the ribonucleotide reductase M1 gene. Clin Cancer Res 2008, 14: 3083-3088
14. Gautam A, Bepler G: Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 2006, 66:6497-6502 (Pubitemid 44085603)
15. Fan H, Huang A, Villegas C, Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 1997, 94:13181-13186
16. Gautam A, Li ZR, Bepler G: RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003, 22:2135-2142
17. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L: RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:1878-1885
18. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800-808
19. Akita H, Zheng Z, Takeda Y, Chiwan K, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nkamori S, Monden M, Mori M, Doki Y, Bepler G: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009, 28:2903-2909
20. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida G, Farabi R, Jassem J: BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007, 2:e1129
21. Saviozzi S, Ceppi P, Novello S, Ghio P, Lo Iacono M, Borasia P, Cambieri A, Volante M, Papotti M, Calogero RA, Scagliotti GV: Nonsmall cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res 2009, 69:3390-3396
22. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G: Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746 (Pubitemid 47123182)
23. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754
24. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, DeMarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815
25. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360
26. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327 (Pubitemid 35373567)
27. Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G: In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest 2010, 28:172-180
28. Gustavson MD, Bourke-Martin B, Reilly D, Cregger M, Williams C, Mayotte J, Zerkowski M, Tedeschi G, Pinard R, Christiansen J: Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 2009, 133:60-66
29. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005, 97:1808-1815